Clinical Trials Directory

Trials / Completed

CompletedNCT02383849

IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

Status
Completed
Phase
Study type
Observational
Enrollment
124 (actual)
Sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Network
Sex
All
Age
7 Days – 84 Days
Healthy volunteers
Not accepted

Summary

P1106 is Phase IV prospective pharmacokinetic (PK) study of low birth weight infants who are receiving or will be receiving as part of clinical care nevirapine (NVP) prophylaxis, tuberculosis (TB) prophylaxis or treatment and/or combination antiretroviral (ARV) treatment containing lopinavir/ritonavir (LPV/r). The study is designed to describe the pharmacokinetics and safety of NVP, INH, RIF, and LPV/r in these infants receiving the drug(s) as part of clinical care.

Conditions

Timeline

Start date
2015-08-04
Primary completion
2020-02-14
Completion
2020-02-14
First posted
2015-03-09
Last updated
2021-08-06

Locations

2 sites across 1 country: South Africa

Source: ClinicalTrials.gov record NCT02383849. Inclusion in this directory is not an endorsement.

IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants (NCT02383849) · Clinical Trials Directory